|
1,415
|
| 9760 |
NR1H4
|
|
decreases_activity of
|
NF-kappaB complex
|
in liver
|
|
18972444
|
Schizophrenia
|
|
3,567
|
| 33327 |
NR1H4
|
|
decreases_activity of
|
gallstones
|
|
| 33328 |
LIRKO mouse
|
|
decreases_expression of
|
NR1H4
|
|
| 33329 |
LIRKO mouse
|
|
affects_activity of
|
NR1H4
|
|
|
18587407
|
Diabetes mellitus, type II
Insulin resistance
Gallbladder disease 1
|
|
3,569
|
| 33366 |
NR1H4
|
NOT |
affects_expression of
|
ABCG5
|
in liver
|
| 33367 |
NR1H4
|
NOT |
affects_expression of
|
ABCG8
|
in liver
|
|
18587407
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,571
|
| 33380 |
NR1H4
|
|
affects_quantity of
|
adipose tissue
|
|
| 33384 |
NR1H4
|
|
affects_activity of
|
decreased circulating leptin level
|
in blood serum
|
| 33386 |
NR1H4
|
|
affects_activity of
|
increased circulating free fatty acid level
|
in blood plasma
|
| 33387 |
NR1H4
|
|
affects_activity of
|
impaired glucose tolerance
|
|
| 33388 |
NR1H4
|
|
affects_activity of
|
Insulin resistance
|
|
| 33389 |
NR1H4
|
|
affects_activity of
|
insulin receptor signaling pathway
|
in white adipose tissue, in skeletal muscle
|
| 33390 |
NR1H4
|
|
affects_phosphorylation of
|
AKT1
|
in white adipose tissue, in skeletal muscle
|
| 33391 |
NR1H4
|
NOT |
is_expressed_in
|
skeletal muscle
|
|
| 33392 |
NR1H4
|
|
is_expressed_in
|
white adipose tissue
|
|
| 33393 |
fat cell differentiation
|
|
increases_expression of
|
NR1H4
|
|
| 33394 |
NR1H4
|
|
affects_activity of
|
fat cell differentiation
|
|
| 33395 |
NR1H4
|
NOT |
affects_expression of
|
PPARG
|
in white adipose tissue
|
| 33403 |
NR1H4
|
NOT |
affects_expression of
|
CEBPA
|
in white adipose tissue
|
| 33404 |
NR1H4
|
NOT |
affects_expression of
|
FABP4
|
in white adipose tissue
|
| 33405 |
NR1H4
|
|
affects_expression of
|
CEBPB
|
in white adipose tissue
|
| 33406 |
NR1H4
|
|
affects_expression of
|
SREBF1c
|
in white adipose tissue
|
| 33407 |
NR1H4
|
|
affects_expression of
|
LEP
|
in white adipose tissue
|
| 33408 |
NR1H4
|
NOT |
affects_expression of
|
ADIPOQ
|
in white adipose tissue
|
| 33409 |
NR1H4
|
NOT |
affects_expression of
|
RETN
|
in white adipose tissue
|
| 33410 |
NR1H4
|
NOT |
affects_expression of
|
IL6
|
in white adipose tissue
|
| 33411 |
NR1H4
|
|
affects_expression of
|
TNF
|
in white adipose tissue
|
| 33412 |
NR1H4
|
NOT |
affects_expression of
|
DGAT1
|
in white adipose tissue
|
| 33413 |
NR1H4
|
NOT |
affects_expression of
|
FASN
|
in white adipose tissue
|
| 33414 |
NR1H4
|
NOT |
affects_expression of
|
PCK1
|
in white adipose tissue
|
| 33415 |
NR1H4
|
|
affects_expression of
|
LIPE
|
in white adipose tissue
|
| 33416 |
NR1H4
|
|
affects_expression of
|
LPL
|
in white adipose tissue
|
| 33417 |
NR1H4
|
|
affects_expression of
|
SLC27A1
|
in white adipose tissue
|
| 33418 |
NR1H4
|
|
affects_expression of
|
PPARA
|
in skeletal muscle
|
| 33419 |
NR1H4
|
|
affects_expression of
|
PPARD
|
in skeletal muscle
|
| 33420 |
NR1H4
|
|
affects_expression of
|
SLC27A1
|
in skeletal muscle
|
| 33421 |
NR1H4
|
|
affects_expression of
|
LPL
|
in skeletal muscle
|
| 33422 |
NR1H4
|
|
affects_expression of
|
DGAT1
|
in skeletal muscle
|
| 33423 |
NR1H4
|
|
affects_expression of
|
CPT1B
|
in skeletal muscle
|
| 33424 |
NR1H4
|
|
affects_expression of
|
UCP2
|
in skeletal muscle
|
| 33425 |
NR1H4
|
|
affects_expression of
|
UCP3
|
in skeletal muscle
|
| 33426 |
NR1H4
|
|
affects_expression of
|
ACO
|
in skeletal muscle
|
|
16446356
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,576
|
| 33528 |
NR1H4
|
|
is_expressed_in
|
pancreatic beta cell
|
|
| 33529 |
NR1H4
|
|
increases_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
|
| 33531 |
NR1H4
|
|
is_expressed_in
|
intestine
|
|
| 33590 |
NR1H4
|
|
decreases_expression of
|
SREBF1
|
in liver; via LXR
|
| 33592 |
NR1H4
|
|
decreases_activity of
|
VLDL secretion
|
in liver
|
| 33593 |
NR1H4
|
|
decreases_activity of
|
ectopic lipid storage
|
in liver
|
| 33595 |
NR1H4
|
|
increases_expression of
|
APOC2
|
in liver
|
| 33596 |
NR1H4
|
|
decreases_expression of
|
APOC3
|
in liver
|
| 33597 |
NR1H4
|
|
decreases_expression of
|
CYP7A1
|
in liver
|
| 33598 |
NR1H4
|
|
increases_expression of
|
ABCB11
|
in liver
|
| 33599 |
NR1H4
|
|
decreases_expression of
|
SLC10A1
|
in liver
|
| 33604 |
NR1H4
|
|
increases_expression of
|
SLC51A
|
in intestine
|
| 33607 |
NR1H4
|
|
increases_expression of
|
SLC51B
|
in intestine
|
| 33610 |
NR1H4
|
|
increases_expression of
|
FABP6
|
in intestine
|
| 33612 |
NR1H4
|
|
increases_expression of
|
FGF19
|
in intestine
|
| 33614 |
NR1H4
|
|
decreases_expression of
|
APOA1
|
in liver
|
| 33618 |
NR1H4
|
|
decreases_expression of
|
LDLR
|
in liver
|
| 33619 |
NR1H4
|
|
increases_expression of
|
ABCG5
|
in liver
|
| 33620 |
NR1H4
|
|
increases_expression of
|
ABCG8
|
in liver
|
| 33621 |
NR1H4
|
|
increases_expression of
|
SCARB1
|
in liver
|
| 33623 |
NR1H4
|
|
decreases_expression of
|
PCSK9
|
in liver
|
|
21991404
|
Diabetes mellitus, type II
Cholestasis, progressive familial intrahepatic 2
Insulin resistance
|
|
3,609
|
| 34059 |
NR1H4
|
|
is_expressed_in
|
pancreatic islet
|
|
| 34060 |
NR1H4
|
|
increases_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
|
| 34061 |
NR1H4
|
|
affects_expression of
|
INS
|
|
| 34062 |
NR1H4
|
|
increases_transport of
|
SLC2A2
|
to the plasma membrane
|
| 34063 |
NR1H4
|
|
increases_activity of
|
glucose import
|
in pancreas, in pancreatic beta cells
|
| 34064 |
NR1H4
|
|
increases_phosphorylation of
|
AKT1
|
in pancreas, in pancreatic beta cells
|
| 34065 |
NR1H4
|
|
increases_activity of
|
protein kinase B signaling
|
in pancreas, in pancreatic beta cells
|
| 34066 |
NR1H4
|
NOT |
affects_expression of
|
SLC2A2
|
in pancreas, in pancreatic beta cells
|
| 34067 |
NR1H4
|
|
increases_expression of
|
KLF11
|
in pancreas
|
|
20060466
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,610
|
| 34068 |
NR1H4
|
|
affects_activity of
|
Diabetes mellitus, type I
|
|
| 34069 |
NR1H4
|
|
increases_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
|
| 34070 |
NR1H4
|
|
increases_expression of
|
SLC2A4
|
in liver
|
|
20060466
|
Diabetes mellitus, type I
|
|
3,615
|
| 34141 |
Cholic acid
|
NOT |
affects_expression of
|
NR1H4
|
in brown adipose tissue
|
|
16400329
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
3,632
|
| 34412 |
Chenodeoxycholate
|
|
increases_activity of
|
NR1H4
|
|
| 34413 |
Lithocholic acid
|
|
increases_activity of
|
NR1H4
|
|
| 34414 |
Deoxycholic acid
|
|
increases_activity of
|
NR1H4
|
|
| 34415 |
Cholic acid
|
|
increases_activity of
|
NR1H4
|
|
| 34419 |
NR1H4
|
|
interacts (colocalizes) with
|
RXR
|
|
| 34420 |
NR1H4
|
|
increases_expression of
|
NR0B2
|
|
| 34421 |
NR1H4
|
|
increases_expression of
|
FGF19
|
in intestine
|
| 34428 |
Diabetes mellitus, type II
|
|
decreases_expression of
|
NR1H4
|
|
| 34432 |
NR1H4
|
|
affects_expression of
|
PKLR
|
|
| 34433 |
NR1H4
|
|
affects_expression of
|
FASN
|
|
| 34434 |
NR1H4
|
|
affects_expression of
|
ACACA
|
|
| 34435 |
NR1H4
|
|
decreases_activity of
|
gluconeogenesis
|
|
| 34436 |
NR1H4
|
|
decreases_expression of
|
PCK1
|
|
| 34438 |
NR1H4
|
|
decreases_expression of
|
G6PC
|
|
| 34439 |
NR1H4
|
|
decreases_expression of
|
FBP1
|
|
| 34441 |
NR1H4
|
|
affects_activity of
|
Insulin resistance
|
in peripheral tissues
|
| 34442 |
NR1H4
|
|
affects_activity of
|
insulin secretion involved in cellular response to glucose stimulus
|
|
| 34445 |
NR1H4
|
|
affects_activity of
|
hyperlipidemia
|
|
| 34456 |
NR1H4
|
|
affects_quantity of
|
adipose tissue
|
|
| 34485 |
NR1H4
|
|
affects_activity of
|
fat cell differentiation
|
via PPARG and Wnt pathway
|
| 34486 |
NR1H4
|
|
increases_activity of
|
PPARG
|
|
| 34487 |
NR1H4
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
|
| 34488 |
NR1H4
|
|
affects_activity of
|
lipid catabolic process
|
|
| 34489 |
NR1H4
|
|
affects_activity of
|
lipid biosynthetic process
|
|
| 34490 |
NR1H4
|
|
increases_activity of
|
glucose import
|
|
| 34517 |
NR1H4
|
|
increases_activity of
|
LPL
|
|
| 34518 |
NR1H4
|
|
increases_expression of
|
LDLR
|
in vitro
|
| 34522 |
NR1H4
|
|
decreases_expression of
|
PCSK9
|
in vitro
|
| 34526 |
NR1H4
|
|
decreases_expression of
|
APOA1
|
|
| 34531 |
NR1H4
|
|
increases_expression of
|
SCARB1
|
in liver
|
| 34535 |
NR1H4
|
|
increases_activity of
|
decreased circulating HDL cholesterol level
|
|
| 34543 |
NR1H4
|
|
decreases_activity of
|
liver fibrosis
|
in liver; caused by inflammatory cell infiltration
|
| 34546 |
NR1H4
|
|
decreases_expression of
|
TGFB1
|
|
| 34547 |
NR1H4
|
|
decreases_expression of
|
TIMP1
|
|
|
21431855
|
Diabetes mellitus, type II
Obesity
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
3,646
|
| 34559 |
Bile salt
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 34560 |
NR1H4
|
|
is_expressed_in
|
liver
|
|
| 34595 |
NR1H4
|
|
is_expressed_in
|
intestine
|
|
| 34596 |
NR1H4
|
|
is_expressed_in
|
kidney
|
|
| 34599 |
NR1H4
|
|
is_expressed_in
|
adrenal gland
|
|
| 34600 |
NR1H4
|
|
affects_activity of
|
bile acid metabolic process
|
|
| 34609 |
NR1H4
|
|
affects_activity of
|
abnormal intestinal barrier
|
|
| 34612 |
NR1H4
|
|
affects_activity of
|
abnormal innate immunity
|
|
| 34613 |
NR1H4
|
|
affects_activity of
|
neoplasm
|
|
| 34615 |
NR1H4
|
|
decreases_activity of
|
increased bile salt level
|
in liver
|
| 34617 |
NR1H4
|
|
decreases_activity of
|
bile acid biosynthetic process
|
in liver
|
| 34619 |
NR1H4
|
|
increases_activity of
|
bile acid excretion
|
|
| 34621 |
NR1H4
|
|
decreases_expression of
|
SREBF1c
|
via NR0B2 activation
|
| 34625 |
NR1H4
|
|
decreases_activity of
|
fatty acid biosynthetic process
|
via SREBF1c repression
|
| 34626 |
NR1H4
|
|
decreases_activity of
|
triglyceride biosynthetic process
|
via SREBF1c repression
|
| 34628 |
NR1H4
|
|
increases_activity of
|
very-low-density lipoprotein particle clearance
|
via increased VLDLR expression
|
| 34630 |
NR1H4
|
|
increases_activity of
|
chylomicron remnant clearance
|
via increased VLDLR expression
|
| 34631 |
NR1H4
|
|
increases_expression of
|
VLDLR
|
|
| 34632 |
NR1H4
|
|
affects_activity of
|
very-low-density lipoprotein particle assembly
|
via MTTP and APOB repression
|
| 34633 |
NR1H4
|
|
decreases_expression of
|
MTTP
|
|
| 34635 |
NR1H4
|
|
decreases_expression of
|
APOB
|
|
| 34636 |
NR1H4
|
|
increases_activity of
|
SDC1
|
|
| 34637 |
NR1H4
|
|
increases_activity of
|
LPL
|
|
| 34638 |
NR1H4
|
|
increases_activity of
|
APOC2
|
|
| 34639 |
NR1H4
|
|
increases_activity of
|
APOA4
|
|
| 34640 |
NR1H4
|
|
decreases_expression of
|
APOC3
|
|
| 34641 |
NR1H4
|
|
decreases_expression of
|
ANGPTL3
|
|
| 34643 |
NR1H4
|
|
increases_expression of
|
PPARA
|
|
| 34645 |
NR1H4
|
|
decreases_activity of
|
increased circulating triglyceride level
|
|
| 34646 |
NR1H4
|
|
decreases_activity of
|
Fatty liver disease, nonalcoholic
|
|
| 34647 |
NR1H4
|
|
affects_activity of
|
cholesterol metabolic process
|
|
| 34648 |
NR1H4
|
|
affects_activity of
|
increased susceptibility to atherosclerosis
|
|
| 34649 |
NR1H4
|
|
affects_activity of
|
glucose homeostasis
|
|
| 34651 |
NR1H4
|
|
decreases_activity of
|
hyperglycemia
|
|
| 34652 |
NR1H4
|
|
decreases_activity of
|
hyperlipidemia
|
|
| 34653 |
NR1H4
|
|
decreases_activity of
|
I-kappaB kinase/NF-kappaB signaling
|
in liver
|
| 34655 |
NR1H4
|
|
decreases_activity of
|
inflammatory response
|
in liver
|
| 34657 |
NR1H4
|
|
decreases_activity of
|
liver fibrosis
|
|
| 34662 |
NR1H4
|
|
decreases_expression of
|
TGFB1
|
in liver
|
| 34663 |
NR1H4
|
|
decreases_expression of
|
TIMP1
|
in liver
|
| 34664 |
NR1H4
|
|
decreases_expression of
|
COL1A1
|
in liver
|
| 34665 |
NR1H4
|
|
decreases_expression of
|
ACTA2
|
in liver
|
| 34666 |
NR1H4
|
|
decreases_expression of
|
MMP2
|
in liver
|
| 34668 |
NR1H4
|
|
decreases_expression of
|
COL1A2
|
in liver
|
| 34669 |
NR1H4
|
|
decreases_expression of
|
mir-29a
|
in liver
|
|
22187656
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
4,598
|
| 45882 |
NR1H4
|
|
decreases_expression of
|
CYP19A1
|
in breast cancer cells
|
| 45883 |
NR1H4
|
|
decreases_expression of
|
UGT2B15
|
in prostate cancer cells
|
| 45884 |
NR1H4
|
|
decreases_expression of
|
UGT2B17
|
in prostate cancer cells
|
| 45885 |
NR1H4
|
|
increases_activity of
|
SULT2A1
|
|
|
19762543
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,387
|
| 61646 |
SIRT1
|
|
affects_activity of
|
NR1H4
|
|
|
25955819
|
Metabolic
|
|
6,606
|
| 63634 |
Bile salt
|
|
increases_activity of
|
NR1H4
|
|
| 63635 |
NR1H4
|
|
increases_activity of
|
FGF19
|
in intestine
|
| 63678 |
Chenodeoxycholate
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 63679 |
Lithocholic acid
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 63680 |
Deoxycholic acid
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 63681 |
Cholic acid
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 63682 |
NR1H4
|
|
affects_activity of
|
bile acid biosynthetic process
|
|
| 63683 |
NR1H4
|
|
affects_activity of
|
enterohepatic circulation
|
|
| 63684 |
NR1H4
|
|
affects_activity of
|
glucose metabolic process
|
|
| 63685 |
NR1H4
|
|
affects_activity of
|
lipoprotein metabolic process
|
|
| 63686 |
NR1H4
|
|
affects_activity of
|
lipid metabolic process
|
|
| 63687 |
NR1H4
|
|
affects_activity of
|
inflammatory response
|
|
| 63688 |
NR1H4
|
|
affects_activity of
|
defense response to tumor cell
|
|
|
26579434
|
Colorectal cancer
Diabetes mellitus, type II
Insulin resistance
|
|
6,607
|
| 63738 |
Bile salt
|
|
increases_activity of
|
NR1H4
|
|
| 63739 |
NR1H4
|
|
increases_activity of
|
FGF19
|
|
| 63743 |
NR1H4
|
|
affects_expression of
|
ABCB11
|
in liver
|
| 63772 |
NR1H4
|
|
affects_expression of
|
SLC51A
|
in liver
|
| 63773 |
NR1H4
|
|
affects_expression of
|
SLC51B
|
in liver
|
| 63774 |
NR1H4
|
|
affects_expression of
|
SLC10A1
|
in liver
|
| 63777 |
NR1H4
|
|
affects_expression of
|
NR0B2
|
in liver
|
| 63779 |
Cholic acid
|
|
increases_activity of
|
NR1H4
|
in liver
|
| 63780 |
NR1H4
|
|
decreases_activity of
|
SREBF1c
|
in liver
|
| 63781 |
NR1H4
|
|
decreases_activity of
|
lipid biosynthetic process
|
in liver; via SREBF1c
|
| 63782 |
NR1H4
|
|
decreases_quantity of
|
Triacylglycerol
|
in liver; via SREBF1c
|
| 63783 |
NR1H4
|
|
increases_expression of
|
PPARA
|
in liver
|
| 63784 |
NR1H4
|
|
increases_activity of
|
lipid catabolic process
|
in liver
|
| 63785 |
NR1H4
|
|
increases_activity of
|
fatty acid beta-oxidation
|
in liver
|
| 63786 |
NR1H4
|
|
affects_activity of
|
lipoprotein metabolic process
|
in liver
|
| 63787 |
NR1H4
|
|
affects_activity of
|
lipid transport
|
in liver
|
| 63788 |
NR1H4
|
|
decreases_expression of
|
APOA1
|
in liver
|
| 63789 |
NR1H4
|
|
decreases_expression of
|
APOC2
|
in liver
|
| 63790 |
NR1H4
|
|
increases_expression of
|
APOC3
|
in liver
|
| 63791 |
NR1H4
|
|
increases_expression of
|
VLDLR
|
in liver
|
| 63793 |
NR1H4
|
|
decreases_expression of
|
HNF4A
|
in liver; via NR0B2 activation
|
| 63794 |
NR1H4
|
|
decreases_expression of
|
G6PC
|
in liver; via NR0B2 activation and HNF4A inhibition
|
| 63795 |
NR1H4
|
|
decreases_expression of
|
PCK1
|
in liver; via NR0B2 activation and HNF4A inhibition
|
| 63796 |
NR1H4
|
|
decreases_activity of
|
gluconeogenesis
|
in liver; via NR0B2 activation and HNF4A inhibition
|
| 63797 |
NR1H4
|
|
affects_activity of
|
PPARGC1A
|
in liver
|
| 63798 |
NR1H4
|
|
increases_expression of
|
PDK
|
in liver
|
| 63800 |
NR1H4
|
|
increases_activity of
|
AKT1
|
in liver
|
| 63801 |
NR1H4
|
|
affects_activity of
|
insulin secretion
|
|
| 63802 |
NR1H4
|
|
affects_activity of
|
insulin receptor signaling pathway
|
|
| 63803 |
NR1H4
|
|
affects_expression of
|
SLC10A2
|
in ileum
|
| 63804 |
NR1H4
|
|
affects_expression of
|
SLC51A
|
in ileum
|
| 63805 |
NR1H4
|
|
affects_expression of
|
SLC51B
|
in ileum
|
| 63806 |
NR1H4
|
|
affects_expression of
|
FABP6
|
in ileum
|
| 63807 |
NR1H4
|
|
affects_expression of
|
FGF19
|
in ileum
|
|
26579438
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,612
|
| 62983 |
AMPK
|
|
decreases_activity of
|
NR1H4
|
|
| 63034 |
Metformin
|
|
decreases_activity of
|
NR1H4
|
via AMPK activation
|
| 63042 |
NR1H4
|
|
interacts (colocalizes) with
|
MED1
|
|
| 63045 |
NR1H4
|
|
interacts (colocalizes) with
|
MED13
|
|
| 63047 |
NR1H4
|
|
interacts (colocalizes) with
|
MED14
|
|
| 63048 |
NR1H4
|
|
interacts (colocalizes) with
|
MED24
|
|
| 63049 |
NR1H4
|
|
interacts (colocalizes) with
|
MED17
|
|
| 63050 |
NR1H4
|
|
interacts (colocalizes) with
|
HELZ2
|
|
| 63051 |
NR1H4
|
|
interacts (colocalizes) with
|
CREBBP
|
|
| 63052 |
NR1H4
|
|
interacts (colocalizes) with
|
NCOA3
|
|
| 63053 |
NR1H4
|
|
interacts (colocalizes) with
|
PPARGC1A
|
|
| 63054 |
NR1H4
|
|
interacts (colocalizes) with
|
EP300
|
|
| 63056 |
NR1H4
|
|
interacts (colocalizes) with
|
ARID1A
|
|
| 63057 |
NR1H4
|
|
interacts (colocalizes) with
|
BAF60
|
|
| 63058 |
NR1H4
|
|
interacts (colocalizes) with
|
MTA1
|
|
| 63059 |
NR1H4
|
|
interacts (colocalizes) with
|
NRIP1
|
|
| 63060 |
NR1H4
|
|
interacts (colocalizes) with
|
PRKAG2
|
|
| 63061 |
NR1H4
|
|
interacts (colocalizes) with
|
PARP1
|
|
| 63062 |
NR1H4
|
|
interacts (colocalizes) with
|
TOP2
|
|
|
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,617
|
| 63035 |
Metformin
|
|
decreases_activity of
|
NR1H4
|
via phosphorylation
|
|
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,415
|
| 73005 |
APOE KO mouse
|
|
decreases_expression of
|
NR1H4
|
in liver; 1.97 fold, when fed with 1.25% cholesterol;
|
| 73179 |
Bile salt
|
|
increases_activity of
|
NR1H4
|
|
| 73180 |
PPARGC1A
|
|
increases_activity of
|
NR1H4
|
via two pathways
|
| 73188 |
NR1H4
|
|
increases_activity of
|
NR1H4-NR0B2-SREBF1c regulatory cascade
|
|
| 73194 |
PPARGC1A
|
|
increases_expression of
|
NR1H4
|
|
| 73195 |
PPARGC1A
|
|
interacts (colocalizes) with
|
NR1H4
|
|
|
21857965
|
Alzheimer disease
Metabolic
|
|
7,526
|
| 74218 |
Bile salt
|
|
increases_activity of
|
NR1H4
|
in hepatocytes
|
| 74220 |
NR1H4
|
|
increases_expression of
|
FGF19
|
in the intestine; when bile acid‚Äďactivated
|
| 74231 |
NR1H4
|
|
increases_expression of
|
NR0B2
|
in hepatocytes
|
| 74738 |
NR1H4
|
|
affects_expression of
|
ABCB4
|
|
| 74739 |
NR1H4
|
|
affects_expression of
|
ATP8B1
|
|
| 74746 |
NR1H4-mut
|
|
affects_activity of
|
NR1H4
|
|
| 75057 |
NR1H4
|
|
is_expressed_in
|
liver
|
|
| 75058 |
NR1H4
|
|
is_expressed_in
|
intestine
|
|
| 75059 |
NR1H4
|
NOT |
is_expressed_in
|
skeletal muscle
|
|
| 75060 |
NR1H4
|
|
is_expressed_in
|
white adipose tissue
|
at a very low level
|
| 75315 |
Chenodeoxycholate
|
|
increases_activity of
|
NR1H4
|
The hydrophobic bile acid CDCA is the most efficacious ligand of FXR.
|
| 75317 |
NR1H4
|
|
increases_expression of
|
ABCB11
|
|
| 75318 |
NR1H4
|
|
decreases_expression of
|
SLC10A1
|
presumably via induction of SHP
|
| 75319 |
Chenodeoxycholate
|
|
interacts (colocalizes) with
|
NR1H4
|
The hydrophobic bile acid CDCA is the most efficacious ligand of FXR.
|
| 75320 |
Lithocholic acid
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 75321 |
Lithocholic acid
|
|
increases_activity of
|
NR1H4
|
|
| 75322 |
NR1H4
|
|
increases_activity of
|
NR0B2
|
in hepatocytes
|
| 75323 |
Deoxycholic acid
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 75324 |
Deoxycholic acid
|
|
increases_activity of
|
NR1H4
|
|
| 75325 |
Cholic acid
|
|
interacts (colocalizes) with
|
NR1H4
|
|
| 75326 |
Cholic acid
|
|
increases_activity of
|
NR1H4
|
|
| 75327 |
Ursodeoxycholic acid
|
NOT |
affects_activity of
|
NR1H4
|
|
| 75331 |
NR1H4
|
|
increases_expression of
|
ABCC2
|
|
| 75332 |
NR1H4
|
|
increases_expression of
|
ABCB4
|
|
| 75333 |
NR1H4
|
|
increases_expression of
|
ABCG5
|
|
| 75334 |
NR1H4
|
|
increases_expression of
|
ABCG8
|
|
| 75343 |
NR1H4
|
|
decreases_expression of
|
CYP7A1
|
|
| 75365 |
NR1H4
|
|
affects_expression of
|
CYP8B1
|
|
| 75373 |
NR1H4
|
|
decreases_expression of
|
SLC10A1
|
|
| 75400 |
NR1H4
|
|
increases_expression of
|
SLC51A
|
at the sinusoidal membrane; if FXR is activated;
|
| 75401 |
NR1H4
|
|
increases_expression of
|
SLC51B
|
at the sinusoidal membrane; if FXR is activated;
|
| 75404 |
NR1H4
|
|
affects_expression of
|
FABP6
|
|
| 75413 |
NR1H4
|
|
increases_activity of
|
FGF19
|
in the intestine; when bile acid‚Äďactivated
|
| 75475 |
NR1H4
|
|
decreases_expression of
|
PCK1
|
in primary hepatocytes and in liver cell lines; by inducing SHP
|
| 75478 |
NR1H4
|
|
decreases_quantity of
|
Free fatty acid
|
when FXR is activated
|
| 75488 |
NR1H4
|
|
decreases_expression of
|
G6PC
|
in primary hepatocytes and in liver cell lines; by inducing SHP
|
| 75490 |
NR1H4
|
|
interacts (colocalizes) with
|
PCK1 (promoter)
|
|
| 75502 |
NR1H4
|
|
increases_activity of
|
increased insulin sensitivity
|
|
| 75510 |
6-ECDCA
|
|
increases_activity of
|
NR1H4
|
|
| 75826 |
NR1H4
|
|
decreases_activity of
|
gut microbiota
|
via bile acid activation;
|
| 75843 |
gut microbiota
|
|
affects_activity of
|
NR1H4
|
via regulating bile acid biotransformation in the intestine and therefore altering bile acid composition;
|
| 75967 |
Tauro-alpha-muricholic acid
|
|
decreases_activity of
|
NR1H4
|
confirmed by a recent study of germ-free mice;
|
| 76011 |
Tauro-beta-muricholic acid
|
|
decreases_activity of
|
NR1H4
|
confirmed by a recent study of germ-free mice;
|
| 76041 |
NR1H4
|
|
decreases_activity of
|
MLXIPL
|
if FXR is activated;
|
| 76093 |
NR1H4
|
|
interacts (colocalizes) with
|
MLXIPL
|
|
| 76098 |
NR1H4
|
|
increases_expression of
|
PPARA
|
|
| 76099 |
NR1H4
|
|
increases_expression of
|
FGF21
|
in liver
|
| 76100 |
NR1H4
|
|
increases_expression of
|
APOC2
|
if FXR is activated
|
| 76101 |
NR1H4
|
|
increases_expression of
|
VLDLR
|
if FXR is activated;
|
| 76103 |
Glucose
|
|
increases_modification of
|
NR1H4
|
FXR was O-Glc-N-acylated under high glucose concentration;
|
| 76134 |
NR1H4
|
|
decreases_quantity of
|
Triacylglycerol
|
|
| 76138 |
NR1H4
|
|
increases_expression of
|
APOA5
|
if FXR is activated
|
| 76139 |
NR1H4
|
|
decreases_expression of
|
APOC3
|
if FXR is activated
|
| 76147 |
NR1H4
|
|
increases_activity of
|
cellular glucose flux
|
when FXR was O-Glc-N-acylated under high glucose concentration;
|
| 76148 |
NR1H4
|
|
increases_transport of
|
Glucose
|
when FXR was O-Glc-N-acylated under high glucose concentration;
|
| 76149 |
NR1H4
|
|
increases_activity of
|
hexoseamine biosynthetic pathway
|
when FXR was O-Glc-N-acylated under high glucose concentration;
|
| 99274 |
NR1H4
|
|
increases_activity of
|
NR1H4 signaling
|
|
|
25073467
|
Gastrointestinal
Metabolic
|
|
7,530
|
| 74758 |
Bile salt
|
|
affects_activity of
|
NR1H4
|
|
|
28235194
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,584
|
| 75440 |
GW 4064
|
|
increases_activity of
|
NR1H4
|
|
| 75441 |
Fexaramine
|
|
increases_activity of
|
NR1H4
|
|
| 75442 |
Chenodeoxycholate
|
|
increases_activity of
|
NR1H4
|
|
|
15564327
|
Metabolic
|
|
7,585
|
| 75452 |
GW 4064
|
|
increases_activity of
|
NR1H4
|
|
|
15564327
|
Metabolic
|
|
7,607
|
| 76005 |
NR1H4
|
|
decreases_expression of
|
APOA1
|
in HepG2 cells
|
|
26813964
|
Metabolic
|
|
7,627
|
| 76323 |
NR1H4
|
|
is_expressed_in
|
brain
|
in human brain, in cortex
|
| 76387 |
NR1H4
|
|
is localized in
|
nucleus
|
in cultured mouse neurons
|
| 76388 |
NR1H4
|
|
increases_expression of
|
NR0B2
|
in cultured mouse neurons and in mouse brain tissues; if FXR is activated;
|
| 76393 |
NR1H4
|
|
is localized in
|
cytoplasm
|
in mouse neurons in vivo
|
|
27545319
|
Metabolic
|
|
7,632
|
| 76425 |
Chenodeoxycholate
|
|
increases_activity of
|
NR1H4
|
in mouse substantia nigra-like cell line SN4741 (of neural origin)
|
|
19996111
|
Metabolic
|
|
8,209
|
| 83491 |
Insulin
|
|
decreases_expression of
|
NR1H4
|
|
| 83492 |
Glucose
|
|
increases_expression of
|
NR1H4
|
|
|
24760535
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,210
|
| 83626 |
Bile acid-binding resin
|
|
decreases_activity of
|
NR1H4
|
|
|
24623198
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,585
|
| 88627 |
Bile salt
|
|
affects_activity of
|
NR1H4
|
|
| 88629 |
NR1H4
|
|
increases_expression of
|
FGF19
|
|
| 88632 |
NR1H4
|
|
increases_activity of
|
Obesity
|
|
| 88633 |
NR1H4
|
|
increases_activity of
|
hepatic steatosis
|
|
|
27711063
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,592
|
| 88774 |
NR1H4
|
|
increases_activity of
|
ZFP36L1
|
decreasing the stability of CYP7A1 mRNA
|
| 88788 |
NR1H4
|
|
increases_expression of
|
FGF19
|
in hepatocytes and enterocytes
|
| 88811 |
NR1H4
|
|
decreases_quantity of
|
CYP7A1
|
via decreasing the stability of CYP7A1 mRNA
|
|
29653253
|
Metabolic
|
|
8,605
|
| 88911 |
Bile salt
|
|
interacts (colocalizes) with
|
NR1H4
|
in the intestinal epithelium
|
| 88912 |
NR1H4
|
|
decreases_activity of
|
abnormal gut flora balance
|
|
|
28069752
|
Gastrointestinal
Metabolic
|
|
8,613
|
| 88957 |
NR1H4
|
|
increases_expression of
|
FMO3
|
|
|
29167659
|
Diabetes mellitus, type II
Insulin resistance
Cardiovascular disease
|
CIDeRplus